PARP Inhibitor Delays Uterine Cancer Recurrence in Phase 2 Trial
University of Colorado Anschutz Medical Campus
There are currently no approved maintenance therapies for metastatic and recurrent uterine/endometrial cancer
Research confirms the safety and effectiveness of the first child-friendly single fixed-dose combination HIV treatment